NeuroMetrix, Inc., a healthcare company advancing wearable medical technology to assist both patients and physicians to better manage chronic conditions such as fibromyalgia, recently reported that it has begun to ship its novel Quell devices to healthcare providers across the United States. The firm fielded a direct sales force in April and, as a consequence, more than 100 physicians have purchased Quell to stock and then resell to patients who deal with symptoms related to diseases such as Fibromyalgia.
Dr. Hal Ornstein, a podiatrist in New Jersey and Chairman of the American Academy of Podiatric Practice Management said in a press release: “Patients come to us looking for comprehensive solutions. They expect clinicians to have the latest technology to address their condition. More and more providers are dispensing products like Quell out of their office as they see how it contributes to better care.”
Quell is a wearable device used to relieve pain that utilizes proprietary, non-invasive neurostimulation technology in order to help patients gain relief from chronic, debilitating conditions. The device addresses symptoms related to fibromyalgia, lower back pain, diabetic nerve pain, leg pain and pain caused by osteoarthritis. The innovative, advanced wearable device is lightweight and can be used throughout the day as well as at night during rest and sleep. The Quell device obtained clearance by the United Stated Food and Drug Administration to address treatment of chronic pain, and there is no need for prescription. Those who use the device also have the option of connecting their smartphones to personalize and track their pain therapy by installing the Quell Relief app, available and easily obtainable through the Apple app store here.
The company had previously unveiled and demonstrated the “Quell” device at the 2015 International Consumer Electronics show (CES) this week in Las Vegas. NeuroMetrix was founded by Dr. Gozani in 1996 and, according to the company estimates, more than 2.5 million patients have benefited from its technologies over the past 15 years.